Anti-Mouse PD-L2 (B7-DC) (Clone TY25) – Purified in vivo PLATINUM™ Functional Grade
Anti-Mouse PD-L2 (B7-DC) (Clone TY25) – Purified in vivo PLATINUM™ Functional Grade
Product No.: C9222
Clone TY25 Target PD-L2 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names PD-L2 , CD273, B7-DC Isotype Rat IgG2a κ Applications FC , IHC FF , in vivo , IP , WB |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Isotype Controls Recommended Dilution Buffer Immunogen Purified transfected mouse B7-DC cell line Product Concentration ≥ 5.0 mg/ml Endotoxin Level ≤ 0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM<sup>TM</sup> antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2893592 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for this CD273 antibody clone TY25 for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. WB Additional Applications Reported In Literature ? IHC FF IP Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone TY25 recognizes an epitope on mouse PD-L2. TY25 does not cross-react with PD-L1.
Background PD-L2 antibody, clone TY25, recognizes mouse programmed death ligand 2 (PDL-2), also known as B7-DC and CD273. PD-L2 is a 42 kDa type I transmembrane glycoprotein that belongs to the B7 family of the immunoglobulin (Ig) receptor superfamily. PD-L2 is an inhibitory ligand primarily expressed on antigen-presenting cells, including macrophages and a subset of dendritic cells (DCs). Its receptor, PD-1, is expressed by CD4-CD8- thymocytes as well as CD4 and CD8 T cells, monocytes, DCs, and B cells upon activation1. Binding of PD-L2 to PD-1 on CD4 and CD8 T cells inhibits T cell receptor (TCR) signaling, negatively regulating T cell proliferation, cytokine production, and cytotoxic activity2. PD-L2 is expressed on many tumor types3,4 and is associated with unfavorable prognosis in patients with solid tumors5.
Antigen Distribution PD-L2 is expressed on macrophages and a subset of dendritic cells (DCs). Ligand/Receptor PD-1, uncharacterized receptor PubMed NCBI Gene Bank ID UniProt.org Research Area Costimulatory Molecules . Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone TY25, a rat IgG2a monoclonal antibody targeting mouse PD-L2 (programmed death ligand 2, also known as B7-DC or CD273), is primarily used in blocking studies to investigate immune checkpoint interactions in vivo. The antibody has been specifically reported to block PD-1 mediated interactions when administered to mice. Primary Research ApplicationsThe most common in vivo application of clone TY25 is PD-1/PD-L2 pathway blockade to study immune regulation. PD-L2 naturally binds to its receptor PD-1, which is found on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. This interaction leads to inhibition of TCR-mediated T cell proliferation and cytokine production. By blocking this pathway with TY25, researchers can investigate the functional consequences of PD-L2-mediated immune suppression in various disease models. Clone TY25 is also occasionally used for depleting or detecting PD-L2-expressing cells in mouse models. Since PD-L2 is expressed on monocytes, macrophages, and subsets of dendritic cells, the antibody enables researchers to manipulate or track these antigen-presenting cell populations in vivo. Technical Specifications for In Vivo UseThe antibody is manufactured specifically for in vivo research with strict quality controls, including endotoxin levels below 1.0 EU/mg, and some formulations achieving less than 0.5 EU/mg. It demonstrates high purity (≥95-98% monomer by analytical SEC) and does not cross-react with PD-L1, ensuring specificity in experimental systems. The antibody is produced in animal-free facilities using in vitro cell culture techniques, making it suitable for sensitive in vivo experiments where contamination could confound results. Based on the available search results, specific information about antibodies or proteins commonly used with TY25 in the literature is not provided. The search results mention TY25 as an anti-mouse PD-L2 (B7-DC) antibody, but they do not detail which other antibodies or proteins are frequently used alongside it in research studies. TY25 is identified as an antibody targeting CD273 (also known as PD-L2 or B7-DC), which is part of the B7 family of immune checkpoint molecules. While the search results reference various immune-related antibodies and proteins in other contexts—such as anti-CD25 antibodies, anti-PD-1 antibodies, and other checkpoint molecules—these are not specifically linked to co-usage with TY25 in the literature. To obtain comprehensive information about antibodies and proteins commonly paired with TY25 in experimental protocols or research publications, you would need to consult primary research articles or specialized immunology databases that specifically discuss PD-L2/B7-DC research applications. Key Findings from Clone TY25 Citations in Scientific Literature Clone TY25 is a monoclonal antibody used for targeting Mouse PD-L2. Key findings from its citations in scientific literature focus on its utility in immunology research:
Overall, Clone TY25 is recognized for its versatility in immunological research, facilitating the study of immune cell interactions and differentiation. Dosing Regimens of Clone TY25 (Anti-Mouse PD-L2) in Mouse ModelsCurrent Knowledge on TY25 Dosing There is no standardized dosing regimen for clone TY25 (anti-mouse PD-L2, also known as anti-CD273/B7-DC) in in vivo mouse models. Unlike other commonly used antibodies such as anti-CTLA-4 (clone 9H10 or 9D9), anti-CD4 (GK1.5), or anti-CD8 (2.43), there are no peer-reviewed guidelines or widely accepted dose ranges for TY25 in therapeutic or experimental mouse studies. Flow Cytometry Staining Guidance For flow cytometry applications, the manufacturer suggests using ≤ 0.25 μg per 10⁶ cells in a volume of 100 μl, with titration recommended for optimal performance in each application. However, this guidance is for in vitro staining, not for in vivo administration. In Vivo Use: Lack of Consensus For in vivo studies, each investigator must empirically determine the optimal dose based on their specific experimental model, endpoint, and antibody lot. This is in stark contrast to better-characterized antibodies, where "complete in vivo antibody dosing guides" provide standard ranges (e.g., 100–250 μg per mouse for anti-CTLA-4, 200–250 μg per mouse for anti-CD4, etc.). The lack of published data on TY25 suggests that its use in vivo is uncommon or confined to specialized research contexts. Comparison Table: TY25 vs. Other Common Antibodies
Recommendations for Researchers
ConclusionDosing regimens for clone TY25 in mouse models are not established in the literature or by consensus—in stark contrast to other immunomodulatory antibodies. Each laboratory must determine appropriate doses empirically, guided by experimental objectives and pilot data. The lack of standardization underscores the need for further preclinical characterization of this antibody. References & Citations1. Francisco LM, et al. (2010) Immunol Rev. 236:219-242 2. Latchman Y, et al. (2001) Nat Immunol. 2(3):261-8 3. Ahmad SM, et al. (2018) Oncoimmunology. 7:e1390641 4. Panjwani PK, et al. (2018) Hum Pathol. 71:91–9 5. Yang H, et al. (2019) Front Oncol. 9:47 Technical Protocols IHC FF    Certificate of Analysis |
Related Products
Prod No. | Description |
|---|---|
P379 |
Formats Available
Prod No. | Description |
|---|---|
C2292 | |
C2142 | |
C2296 | |
C2294 | |
C9222 | |
C2295 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
